**Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1-40. (Cancelled).

41. (Currently Amended) An ~~surgical~~ anti-adhesion patch made by the process of mixing a human fibroblast cells capable of organizing a ~~soluble~~ Type I collagen molecules under cell culture conditions whereby the cells organize the ~~soluble~~ Type I collagen molecules into the patch in vitro.

42. (Currently Amended) The anti-adhesion patch of claim 41, further comprising ~~wherein the soluble collagen comprises at least one of type I collagen or~~ type III collagen.

43. (Previously presented) The anti-adhesion patch of claim 41, further comprising at least one of elastin, interstitial collagens, collagen type III, V and IX, glycoproteins or proteoglycans.

44. (Currently Amended) The anti-adhesion patch of claim 41, wherein the Type I collagen molecule is from a natural source or a recombinant source.

45. (Currently Amended) The anti-adhesion patch of claim 41, wherein the cells are ~~autologous, heterologous, xenogeneic or~~ engineered cells.

46. (Previously presented) The anti-adhesion patch of claim 41, wherein the cells are dermal fibroblasts or vascular smooth muscle cell.

47. (Previously presented) The anti-adhesion patch of claim 41, further comprising the step of removing the cells from the patch once the patch has been formed.

48. (Currently Amended) The anti-adhesion patch of claim 41, wherein the patch further comprises a fibrin glue that is disposed on the patch ~~biocompatible bio-adhesive~~.

49. (Previously presented) The anti-adhesion patch of claim 41, wherein patch is adapted for use in the thoracic cavity, ~~abdominal cavity,~~ ophthalmic system, orthopedic system, and the central nervous system~~, reproductive tract and an oral cavity~~.

50. (Previously presented) The anti-adhesion patch of claim 41, further comprising the addition of one or more growth factors selected from fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth

factor beta (TGFβ), transferrin, insulin and serum.

51. (Currently Amended) An ~~surgical~~ anti-adhesion patch made by the process of mixing human fibroblasts capable of organizing ~~a soluble~~ Type I collagen molecules in situ and in vitro under cell culture conditions for 14 days or less, whereby the cells organize the ~~soluble~~ Type I collagen molecule into the patch.

52. (Currently Amended) The anti-adhesion patch of claim 51, further comprising ~~wherein the soluble collagen comprises human type I collagen and~~ human type III collagen.

53. (Previously presented) The anti-adhesion patch of claim 51, further comprising at least one of elastin, interstitial collagens, collagen type III, V and IX, glycoproteins or proteoglycans.

54. (Currently Amended) The anti-adhesion patch of claim 51, wherein the Type I collagen molecule is from a natural source or a recombinant source.

55. (Currently amended) The anti-adhesion patch of claim 51, wherein the cells are ~~autologous, hetereologous, xenogeneic or~~ engineered cells.

56. (Previously presented) The anti-adhesion patch of claim 51, wherein the cells are dermal fibroblasts.

57. (Previously presented) The anti-adhesion patch of claim 51, further comprising the step of removing the cells from the patch once the patch has been formed.

58. (Currently Amended) The anti-adhesion patch of claim 51, wherein the patch further comprises a fibrin glue that is disposed on the patch ~~biocompatible bio-adhesive~~.

59. (Currently Amended) The anti-adhesion patch of claim 51, wherein patch is adapted for use in the thoracic cavity, ~~abdominal cavity,~~ ophthalmic system, orthopedic system, and the central nervous system~~, reproductive tract and an oral cavity~~.

60. (Previously presented) The anti-adhesion patch of claim 51, wherein patch is adapted for attach to the pericardium and prevents adhesions between the epicardium and the pericardium.